Recent advances in proteomic profiling of pancreatic Ductal Adenocarcinoma and the road ahead

Hyunsoo Kim, Joonho Park, Joseph I. Wang, Youngsoo Kim

Research output: Contribution to journalArticle

4 Scopus citations


Introduction: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide. However, there remain many unmet clinical needs, from diagnosis to treatment strategies. The inherent complexity of the molecular characteristics of PDAC has made it difficult to meet these challenges, rendering proteomic profiling of PDAC a critical area of research. Area covered: In this review, we present recent advances in mass spectrometry (MS) and its current application in proteomic studies on PDAC. In addition, we discuss future directions for research that can efficiently incorporate current MS-based technologies that address key issues of PDAC proteomics. Expert commentary: Compared with other cancer studies, little progress has been made in PDAC proteomics, perhaps attributed to the difficulty in performing in-depth and large-scale clinical studies on PDAC. However, recent advances in mass spectrometry can advance PDAC proteomics past the fundamental research stage.

Original languageEnglish
Pages (from-to)963-971
Number of pages9
JournalExpert Review of Proteomics
Issue number11
StatePublished - 5 Oct 2017


  • Biomarker
  • Multiple reaction monitoring
  • Pancreatic ductal adenocarcinoma
  • Quantitative proteomics

Cite this